Skip to main
JNJ

JNJ Stock Forecast & Price Target

JNJ Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 32%
Buy 32%
Hold 37%
Sell 0%
Strong Sell 0%

Bulls say

Johnson & Johnson is expected to continue its strong performance in the healthcare industry, driven by its diverse portfolio and strategic investments in new products and markets. The company's decision to separate its Orthopaedics business and focus on M&A in the MedTech sector shows its commitment to long-term growth and innovation. With a strong financial position and a positive outlook, Johnson & Johnson is well-positioned for continued success in the healthcare market.

Bears say

Johnson & Johnson is a diversified healthcare company, with a focus on innovative medicine and medtech. Despite solid sales growth in 2025 from its MedTech division, there are concerns about market expansion and competitive headwinds in this segment. Additionally, JNJ faces the risk of loss of exclusivity for key drugs and pricing pressures in the pharmaceutical industry. The company's focus on M&A and ongoing litigations add further uncertainty to its outlook. While the company has shown promising potential with new product launches, it may face challenges in maintaining its growth in the highly regulated healthcare industry.

JNJ has been analyzed by 19 analysts, with a consensus rating of Buy. 32% of analysts recommend a Strong Buy, 32% recommend Buy, 37% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Johnson & Johnson and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Johnson & Johnson (JNJ) Forecast

Analysts have given JNJ a Buy based on their latest research and market trends.

According to 19 analysts, JNJ has a Buy consensus rating as of Jul 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $254.79, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $254.79, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Johnson & Johnson (JNJ)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.